Press release
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of new reagent solutions for herpesvirus research, including a range of Human Herpesviruses Antibodies designed to help researchers better understand the structure of Herpesvirus entry and develop new treatments and prevention strategies.The Herpesviridae are a large family of double-stranded DNA enveloped viruses that cause a variety of diseases. The nine human herpesviruses are herpes simplex virus 1 (HSV-1), HSV-2, varicella zoster virus (VZV), human cytomegalovirus (HCMV), human herpesvirus 6A (HHV6A), HHV6B, Epstein-Barr virus (EBV), HHV7, and Kaposi's sarcoma herpesvirus (KSHV). Herpesvirus infections are ubiquitous and establish lifelong latency in infected hosts. Although these viruses infect a variety of cell types, they enter host cells by a conserved mechanism. An understanding of the entry mechanism of these viruses may provide the basis for the design of antiviral drug candidates and subunit vaccines.
Creative Diagnostics now offers new reagent solutions to assist researchers in herpesvirus research, including antibodies that target specific steps in the herpesvirus entry process. Scientists can utilize these antibodies to study how herpesviruses enter cells, facilitating the development of new antiviral drugs.
For example, the Anti-HSV 2 monoclonal antibody (Catalog # CABT-B9084), which reacts with herpes simplex virus type 2 (HSV2) and is specific for the viral glycoprotein D (gD) protein. HSV2 is a member of the Herpesviridae family. HSV1 and HSV2 are very difficult to distinguish from each other, as they have a DNA genome, an icosahedral protein coat, and are encapsulated in a membrane derived from the nuclear membrane of the last host. These viruses are capable of entering an incubation period during which the host shows no visible signs of infection and the level of infectious agents becomes very low. During the latent phase, the viral DNA is integrated into the host genome.
Another example is the Anti-EBV Monoclonal antibody (Catalog # DMAB9761), which is suitable for ELISA and WB. EBV nuclear antigen 1 (EBNA1) is an EBV antigen expressed in all EBV-associated malignancies. It was long thought to be undetectable by the cell-mediated immune system. However, recent studies have shown that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for EBV-associated cancer immunotherapy.
These new reagents can be used to study herpesviruses in the laboratory and to develop assays to detect and measure herpesvirus infection. For more information about Creative Diagnostics' new antibodies for herpesvirus research, please visit https://www.creative-diagnostics.com/the-structure-of-herpesvirus-entry.htm.
Creative Diagnostics
45-1 Ramsey Road, Shirley, NY 11967, USA
Thomas Schmitt
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers' assay development and manufacturing needs.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research here
News-ID: 3132351 • Views: …
More Releases from Creative Diagnostics

Creative Diagnostics Launches Comprehensive Host Cell DNA Assay Kits for Bioproc …
Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, is pleased to announce the launch of its comprehensive suite of Host Cell DNA Assay Kits. These innovative kits empower researchers and manufacturers to effectively detect and quantify residual host cell DNA impurities in biological products, ensuring product safety and regulatory compliance throughout the biopharmaceutical manufacturing process.
The detection of residual host cell DNA throughout the biopharmaceutical manufacturing process…
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facili …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal antibodies, Anti-Fluorescien monoclonal antibodies, and Anti-FAM polyclonal antibodies.
Traditional nucleic acid detection methods require trained operators and sophisticated…
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Resear …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced a series of new ELISA Kits to assist researchers in studing the mechanisms of autoimmunity, including those associated with anti-neotrophil, anti-nuclear, rheumatic diseases, endocrine autoantibodies, and the neurological system.
The immune system has very powerful effector mechanisms to destroy a wide range of pathogens. Early in the study of immunity, it was recognized that if these…
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 fo …
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens, and assay kits, has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. These antibodies can be used in various scientific applications such as WB, ELISA, IHC, and IP to facilitate drug development research.
Coagulation Factor XIIIa (FXIIIa) is a plasma transglutaminase that catalyzes the final step of the coagulation process and plays an important role in hemostasis.…
More Releases for EBV
Epstein-Barr Virus (EBV) Market Generated Opportunities, Future Scope 2025-2032 …
The latest report on the "Epstein-Barr Virus (EBV) Market" by CoherentMI delivers a comprehensive and detailed evaluation of global industry dynamics, uncovering the core trends that shape the competitive landscape. By analyzing key growth drivers, market constraints, emerging opportunities, and sector challenges, the study offers an extensive understanding of the market's behavior. This report is based on rigorously validated research methodologies, ensuring data precision and credibility. It explores critical factors…
Epstein-Barr Virus (EBV) Market Generated Opportunities, Future Scope 2025-2032 …
The Epstein-Barr Virus (EBV) market is estimated to be valued at USD 1.48 Billion in 2025 and is expected to reach USD 2.18 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.
The Latest published market study on Epstein-Barr Virus (EBV) Market report provides an overview of the current market dynamics as well as what our survey respondents- all outsourcing decision-makers- predict the…
Epstein-Barr Virus (EBV) Market Growth 2025: Trends, Consumer Demand, and Key Op …
The Epstein-Barr Virus (EBV) market is estimated to be valued at USD 1.4 Billion in 2024 and is expected to reach USD 2.1 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.53% from 2024 to 2031.
According to the latest research from CoherentMI, the Epstein-Barr Virus (EBV) Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based…
Epstein-Barr Virus (EBV) Market : Growth Opportunities and Projected CAGR 5.53% …
According to a new report published by CoherentMI The Epstein-Barr Virus (EBV) market is estimated to be valued at USD 1.4 Billion in 2024 and is expected to reach USD 2.1 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.53% from 2024 to 2031.
Global Epstein-Barr Virus (EBV) Market Growing Demand and Growth Opportunity 2024-2031: The latest competent intelligence report published by CoherentMI with the title…
Epstein-Barr Virus (EBV) Market A Deep Dive into Current Research, Future Potent …
According to a new report published by CoherentMI The Epstein-Barr Virus (EBV) market is estimated to be valued at USD 1.4 Billion in 2024 and is expected to reach USD 2.1 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.53% from 2024 to 2031.
The Global Epstein-Barr Virus (EBV) Market has recently been analyzed and explored by CoherentMI in their latest market research report. The team…
Epstein-Barr Virus (EBV) Market Sector Size, Growth Trends, and Share Analysis R …
A new Report by CoherentMI Market Reports, titled "Epstein-Barr Virus (EBV) Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Epstein-Barr Virus (EBV) market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The Epstein-Barr Virus (EBV) market is estimated to be valued at USD 1.4 Billion in 2024 and is expected…